Abbvie Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript
All right. Welcome, everyone. This is Gavin Clark-Gartner and Josh Schimmer from the Evercore ISI biotech research team, and we're very happy to be here with the AbbVie team. Full house, we have Rob Michael, who is the Vice Chairman and President; Jeff Stewart, Chief Commercial Officer; Tom Hudson, SVP of R&D and the Chief Scientific Officer; Scott Reents, Chief Financial Officer; and Roopal Thakkar, who's the VP of Regulatory Affairs and R&D Quality Assurance. Thanks for joining us, guys. So we only have 20 minutes today for our fire side. So we're going to dive right into Q&A.
Questions & Answers
And maybe a good place to start is with the Humira biosimilars. So recently, we saw that Optum is putting other biosimilars at parity to Humira. Do you expect more plans to manage biosimilars this way?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
